Diphtheria-tetanus-pertussis compound adjuvant combined vaccine
AssigneeChangchun BCHT Biotechnology Co.
InventorsMengshu WANG, Jun YANG, Tao JIANG, Yanchun WU, Kunming YAN
Life of this patent
Estimating the term…
Abstract
Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.
Claims13
-10. (canceled)
A compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant and/or a pharmaceutically acceptable carrier, wherein the immunogenic composition comprises pertussis PT antigen, pertussis FHA antigen, diphtheria DT antigen, and tetanus TT antigen, and wherein the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist;
- wherein the TLR9 receptor agonist is CpG ODN 2006.
The compound adjuvant combined vaccine according to claim 1, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 1-25 μg of the pertussis PT antigen, 1-25 μg of the pertussis FHA antigen, 1-20 Lf of the diphtheria DT antigen, and 1-5 Lf of the tetanus TT antigen.
The compound adjuvant combined vaccine according to claim 2, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 4, 8, 16, or 25 μg of the pertussis PT antigen, 4, 8, 16, or 25 μg of the pertussis FHA antigen, 1, 2, 4, or 20 Lf of the diphtheria DT antigen, and 1.5, 2.5, or 5 Lf of the tetanus TT antigen.
The compound adjuvant combined vaccine according to claim 3, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 8 μg of the pertussis PT antigen, 8 μg of the pertussis FHA antigen, 2 Lf of the diphtheria DT antigen, and 2.5 Lf of the tetanus TT antigen.
The compound adjuvant combined vaccine according to claim 1, wherein the aluminum adjuvant is aluminum hydroxide.
The compound adjuvant combined vaccine according to claim 1, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 0.01-1 mg of aluminum and 0.1-100 μg of CpG ODN 2006.
The compound adjuvant combined vaccine according to claim 6, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 0.1-0.5 mg of aluminum and 25-100 μg of CpG ODN 2006.
The compound adjuvant combined vaccine according to claim 7, wherein each 0.5 mL dose of the compound adjuvant combined vaccine contains 0.24 mg of aluminum and 50 μg or 100 μg of CpG ODN 2006.
The method according to claim 9, wherein the subject is a mammal.
The method according to claim 10, wherein the subject is a human.
Dependencies are inferred from the claim text.